Clinical Trial Update: Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a phase 1/2 study of the combination of telaglenastat hydrochloride and osimertinib in patients with EGFR-mutate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Telaglenastat hydrochloride (telaglenastat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-19